Placental lactogen Iα inhibitors are a specialized class of chemical compounds that act to suppress the activity of placental lactogen Iα, a hormone predominantly expressed in the placenta. Placental lactogen Iα plays a crucial role in modulating various physiological functions related to energy metabolism and growth regulation during pregnancy. It primarily influences processes such as glucose and lipid metabolism, with its activity contributing to the efficient nutrient transfer between the mother and fetus. Inhibition of placental lactogen Iα can result in altered metabolic pathways, reducing the hormone's ability to promote certain growth and metabolic effects. The compounds that function as inhibitors of this hormone target its binding sites or interfere with its biosynthesis, disrupting its signaling pathways. The specific molecular mechanisms through which these inhibitors exert their effect can vary, ranging from direct antagonism at the receptor level to interference with transcriptional or post-translational modifications.
At the molecular level, placental lactogen Iα inhibitors often exhibit specificity towards key structural domains of the hormone or its receptors, ensuring that they disrupt normal hormone function without significantly affecting other physiological systems. This specificity is vital for studying the hormone's precise role in various metabolic and developmental processes. These inhibitors can be derived from both synthetic and natural sources, and their structures typically consist of complex molecular frameworks designed to interact with the hormone's active sites or its downstream effectors. The study of these inhibitors has deepened understanding of the regulatory mechanisms of placental hormones and has provided valuable insights into the intricate network of endocrine signals that govern fetal development and maternal adaptation during pregnancy. Researchers in biochemical and molecular biology fields often focus on characterizing the interaction profiles, binding affinities, and inhibitory potencies of these compounds to gain further insight into the molecular dynamics of placental lactogen Iα.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Hydrocortisone | 50-23-7 | sc-300810 | 5 g | $102.00 | 6 | |
Hydrocortisone may downregulate PL Iα expression by providing negative feedback to the hypothalamic-pituitary axis, reducing placental hormone production. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $91.00 $139.00 $374.00 | 36 | |
Dexamethasone could decrease PL Iα transcription by binding to glucocorticoid receptors, leading to alterations in gene expression profiles within the placenta. | ||||||
Ellagic Acid, Dihydrate | 476-66-4 | sc-202598 sc-202598A sc-202598B sc-202598C | 500 mg 5 g 25 g 100 g | $58.00 $95.00 $245.00 $727.00 | 8 | |
Ellagic acid may inhibit the expression of PL Iα by interacting with DNA and altering the transcriptional machinery, leading to the suppression of gene activity. | ||||||
Diethylstilbestrol | 56-53-1 | sc-204720 sc-204720A sc-204720B sc-204720C sc-204720D | 1 g 5 g 25 g 50 g 100 g | $71.00 $287.00 $547.00 $1098.00 $2185.00 | 3 | |
Diethylstilbestrol could decrease PL Iα expression by competing with natural estrogens for receptor sites, leading to altered estrogen receptor-mediated gene expression. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
Epigallocatechin Gallate may suppress PL Iα expression through inhibition of specific kinase pathways involved in cell growth and differentiation in placental tissues. | ||||||
Bisphenol A | 80-05-7 | sc-391751 sc-391751A | 100 mg 10 g | $300.00 $490.00 | 5 | |
Bisphenol A may decrease PL Iα expression by mimicking the structure of physiological estrogens, leading to disruption of normal endocrine signaling pathways. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $94.00 $213.00 | 33 | |
Methotrexate could inhibit PL Iα expression by impeding the synthesis of purines and pyrimidines, which are essential for DNA replication and cell division in the placenta. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid may downregulate PL Iα expression by binding to retinoic acid receptors, which can alter the transcription of genes in placental development. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein may inhibit PL Iα expression by acting as a tyrosine kinase inhibitor, thereby disrupting signal transduction processes that control gene expression in the placenta. | ||||||
Lead | 7439-92-1 | sc-250236 | 2 kg | $104.00 | ||
Lead may reduce PL Iα gene expression by inhibiting enzymes involved in the heme pathway, which is crucial for oxygen transport and energy metabolism in placental cells. | ||||||